Valproic Acid With Methylprenisonlone for the Treatment of Acute GVHD
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
aGVHD remains as complication in patients after allogeneic stem cell transplantation.
Methylprednisolone at 1~2mg/kg is considered as standard first-line treatment. In recent lab
study, we demonstrated that valproic acid (VPA) as histone deacetylase inhibitor can inhibit
CD4+ Th1 and Th17 cells and control the aGVDH in mice model while preserve the GVL effects.
In this study, we tested the hypothesis that adding VPA to standard dose steroid treatment
may improve the outcome of aGVHD.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Collaborator:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine